Cancer-Focused Biotech Co. Athenex Launches $72M IPO
Athenex Inc., a biotechnology company developing novel therapies to treat cancer, launched a $72 million initial public offering on Friday under guidance from Sidley Austin LLP, the first of several life...To view the full article, register now.
Already a subscriber? Click here to view full article